Literature DB >> 18813829

Stat3 as a molecular target in RNA interference-based treatment of oral squamous cell carcinoma.

Sebastian Krystian Klosek1, Koh-ichi Nakashiro, Shingo Hara, Hiroyuki Goda, Hiroyuki Hamakawa.   

Abstract

Constitutive activation of signal transducer and activator of transcription 3 (Stat3) has been observed in many human malignancies. Using the sequence-specific RNA interference (RNAi) method to switch off Stat3 expression, it may be possible to arrest cancer growth. In this study, we aimed to identify the most effective sequence of a synthetic small interfering RNA (siRNA) specific for Stat3 (Stat3-siRNA) and the effect of Stat3 suppression on the growth of oral squamous cell carcinoma cells. Ten designed siRNAs with known sequences were screened for the best RNAi effect at the working concentrations of 1 and 10 nM. The range of reduction of Stat3 expression varied from 21 to 67% for 10 nM siRNAs, and from 13 to 73% for 1 nM siRNAs. Three out of the 10 screened siRNAs reduced Stat3 expression to lower levels compared with the GFP-siRNA control. The interferon response of some siRNAs was observed at a concentration of 10 nM. However, at 1 nM, the mRNA levels of interferon response genes (OAS1, OAS2, MX1 and ISFG3gamma) remained unchanged. The growth of GFP-SAS, HSC-3, HSC-4 and KB cells was strongly inhibited by the use of three effective Stat3-siRNAs in comparison with other Stat3-siRNAs and GFP-siRNA. Moreover, the mRNA levels of genes for which transcription is activated by Stat3 were markedly suppressed. These results suggest that targeting Stat3 using siRNA may constitute a useful approach for the treatment of oral squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18813829

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  Down-regulation of STAT3 expression by vector-based small interfering RNA inhibits pancreatic cancer growth.

Authors:  Chen Huang; Guang Yang; Tao Jiang; Jun Cao; Ke-Jian Huang; Zheng-Jun Qiu
Journal:  World J Gastroenterol       Date:  2011-07-07       Impact factor: 5.742

Review 2.  The multifaceted role of STAT3 pathway and its implication as a potential therapeutic target in oral cancer.

Authors:  Elina Khatoon; Mangala Hegde; Aviral Kumar; Uzini Devi Daimary; Gautam Sethi; Anupam Bishyaee; Ajaikumar B Kunnumakkara
Journal:  Arch Pharm Res       Date:  2022-08-20       Impact factor: 6.010

3.  Reversing multidrug-resistant by RNA interference through silencing MDR1 gene in human hepatocellular carcinoma cells subline Bel-7402/ADM.

Authors:  Long Sheng; Maoming Xiong; Cong Li; Xiangling Meng
Journal:  Pathol Oncol Res       Date:  2013-12-11       Impact factor: 3.201

4.  Off-target effects of plasmid-transcribed shRNAs on NFκB signaling pathway and cell survival of human melanoma cells.

Authors:  Kavita Ramji; Dorota Weronika Kulesza; Salem Chouaib; Bozena Kaminska
Journal:  Mol Biol Rep       Date:  2013-10-30       Impact factor: 2.316

5.  Trichothecin Inhibits Cancer-Related Features in Colorectal Cancer Development by Targeting STAT3.

Authors:  Xin Qi; Meng Li; Xiao-Min Zhang; Xiu-Fen Dai; Jian Cui; De-Hai Li; Qian-Qun Gu; Zhi-Hua Lv; Jing Li
Journal:  Molecules       Date:  2020-05-14       Impact factor: 4.411

Review 6.  [Advances of the correlation between JAK-STAT3 signaling pathway and the biological behavior of non-small cell lung cancer].

Authors:  Yang Yu; Zhou Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-02

Review 7.  STAT inhibitors for cancer therapy.

Authors:  Muhammad Furqan; Akintunde Akinleye; Nikhil Mukhi; Varun Mittal; Yamei Chen; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-12-05       Impact factor: 17.388

8.  Therapeutic potential of targeting cell division cycle associated 5 for oral squamous cell carcinoma.

Authors:  Norihiko Tokuzen; Koh-ichi Nakashiro; Hiroshi Tanaka; Kazuki Iwamoto; Hiroyuki Hamakawa
Journal:  Oncotarget       Date:  2016-01-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.